Disclosures. Scleroderma: Early Diagnosis How early is early? 10/28/2013. Difficult Scleroderma: How do I Approach this Patient?
|
|
- Gwendolyn Carson
- 6 years ago
- Views:
Transcription
1 Disclosures Financial support: None Difficult Scleroderma: How do I Approach this Patient? Francesco Boin, MD Assistant Professor of Medicine Director, Translational Research Johns Hopkins Scleroderma Center Investigational medications and/or off label uses discussed in this presentation include: mofetil mycophenolate, cyclophosphamide, prostacyclin, endothelin receptor inhibitors Scleroderma: Early Diagnosis How early is early? Case Study #1 31 years old Caucasian woman presenting with: 2 year history of Raynaud s phenomenon. No digital ulceration Arthralgias and occasional cough over the past 6 months Positive anti-nuclear antibodies (ANA 1: 320) with centromere pattern, anti-rnp, RF and anti-ccp antibodies Pulmonary function tests and chest x-ray are normal Physical examination No skin fibrosis, no joint swelling or effusion Nailfold capillary visualization shows several dilated capillary loops Does this patient have scleroderma? Yes No Maybe Scleroderma: Classification and Clinical Subsets? Type I Type II Type II Early SSc Pre-SSc LIMITED DIFFUSE SSc sine-ssc or Undifferentiated Connective Tissue Disease (UCTD).. Establishing diagnosis of scleroderma 1980 ACR Criteria Must have (a) or two of (b), (c), or (d) CREST Criteria Must have 3 of the 5 features Early SSc Criteria Must have all 3 a. Proximal SSc (proximal to MCPs/MTPs) b. Digital Pits c. Sclerodactyly d. Pulmonary Fibrosis (CXR; HRCT) Calcinosis Raynaud s Phenomenon Esophageal dysmotility Sclerodactyly Telangiectasias a. Definite Raynaud s Phenomenon b. Abnormal Capillary Loops c. Specific Scleroderma Autoantibody Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980 LeRoy EC, Medsger TA Jr. J Rheumatol
2 2013 Classification Criteria for Systemic Sclerosis Skin thickening proximal to MCP joints (sufficient criterion) Skin thickening of the fingers (only count the higher score) Fingertip lesions (only count the higher score) 9 Puffy fingers Sclerodactyly Digital tip ulcers Fingertip pitting scars Telangiectasia 2 Abnormal nailfold capillaries 2 Pulmonary arterial hypertension and/or Interstitial lung disease Raynaud's phenomenon 3 SSc-related autoantibodies (maximum score is 3) Anti centromere Anti topoisomerase I Anti RNA polymerase III 3 Patients with score 9 are classified as having definite Systemic Sclerosis EARLY SSc LeRoy Medsger CLINICAL CASE #1 8 8 Case Study #1 31 years old Caucasian woman presenting with: 2 year history of Raynaud s phenomenon. No digital ulceration Arthralgias and occasional cough over the past 6 months Positive anti-nuclear antibodies (ANA 1: 320) with centromere pattern, anti-rnp, RF and anti-ccp antibodies Pulmonary function tests and chest x-ray are normal Physical examination No skin fibrosis, no joint swelling or effusion Nailfold capillary visualization shows several dilated capillary loops Does this patient have scleroderma? Yes No Maybe Case Study #1 Early-SSc or Pre-SSc What is the best predictor of progression towards definite Scleroderma? Anti-centromere antibodies Nailfold capillary abnormalities New onset of cough History of Raynaud s phenomenon Prevalence of Raynaud s Phenomenon USA 3-5% Spain 3-5% Japan 3% Netherlands 2.9% Italy 2.1% Women > Men Young > Old 15% in young teenager women after menarche When a Connective Tissue Disorder should be suspected? Late age of onset Male gender Asymmetry Severe Raynaud s with ulcerations Positive autoantibodies Nailfold capillary abnormalities 10-15% of patients with Raynaud s may develop a Connective Tissue Disorder Raynaud s Phenomenon Progression to CTD or SSC Follow-up median, years Progression Nailfold capillaries HR=14.4 Nailfold capillaries OR=14.6 Nailfold capillaries OR=21.8 2
3 Case Study #1 Early-SSc or Pre-SSc What is the best predictor of progression towards definite Scleroderma? Digital Capillary Microscopy in Scleroderma Capillary dilatation Anti-centromere antibodies Nailfold capillary abnormalities New onset of cough Capillary loss Hemorrhages Neoangiogenesis History of Raynaud s phenomenon Nailfold Capillary Microscopy Bedside procedure: A drop of immersion oil is placed at the fingernail base; nail fold capillaries are magnified and examined using an ophthalmoscope set at 10 to 40 diopters. Abnormal Nailfold Capillaries UCTD Window of Opportunity Very Early SSc Early SSc Raynaud s Phenomenon Established SSc ANA (95%) Scleroderma-specific autoantibodies (ACA, SCL70, RNAP3) Abnormal Nailfold Capillaries Puffy fingers Scleroderma: Lung Disease Doc, I am getting short of breath! Sclerodactyly SSc Organ involvement Monitoring/Therapy Monitoring/Therapy Adapted from Mattucci-Cerinic et al. Ann Rheum Dis
4 Clinical Case 45 years old Caucasian female presenting on October 2009 with: Raynaud s phenomenon for the past 2 years with digital ulcers Acid reflux (GERD) Fatigue, weight loss Progressive breathlessness Positive ANA 1:320 in speckled pattern Physical Exam Sclerodactyly Bibasilar fine crackles at chest auscultation Pulmonary Function Tests Year FVC DLCO % 71% SSc-dyspnea What would you do next to establish the etiology of this SSc patient s breathlessness? Echocardiogram Repeat PFTs High Resolution Computed Tomography (HRCT) Laboratory testing Right Heart Catheterization Breathlessness (Dyspnea) in Scleroderma Interstitial lung disease Pulmonary Vascular disease Cardiac disease Anemia (GAVE) Myopathy Deconditioning Initial work-up Pulmonary Function Tests HRCT scan ECHO & EKG Basic Labs Special lab tests Pro-BNP CPK Troponin I SSc-dyspnea What would you do next to establish the origin of this SSc patient s breathlessness? Echocardiogram Repeat PFTs High Resolution Computed Tomography (HRCT) Laboratory testing Right Heart Catheterization SSc-ILD SSc-ILD: Facts to Remember ILD occurs in both limited and diffuse skin disease: 70-80% diffuse patients; 15-25% limited patients (SLS data) Not all ILD is bad: had mild or no ILD; 27% had moderate and 13% had severe disease (Steen Arthritis Rheum 1994) 4
5 PERCENT CUMULATIVE SURVIVAL FVC 10/28/2013 Not all ILD is bad YEARS FROM DISEASE ONSET Lowest FVC at any time during course of SSc MINIMAL PULMONARY FIBROSIS N=467 FVC > 75% MODERATE PULMONARY FIBROSIS N=213 FVC 75% and 50% SEVERE PULMONARY FIBROSIS N=116 FVC <50% SSc-ILD: Facts to Remember ILD occurs in both limited and diffuse skin disease: 70-80% diffuse patients; 15-25% limited patients (SLS data) Not all ILD is bad: had mild or no ILD; 27% had moderate and 13% had severe disease (Steen V Arthritis Rheum 1994) While ILD is an early manifestation, late onset and progression occurs Steen VM. Arthritis Rheum 1994 SSc-ILD Loss of Function Course of Lung Disease in SSc Greatest FVC loss within 2-4 years from diagnosis 100% 50% Greater 10% (FVC L) change in 4-6 mo interval is consistent with progressive ILD secondary to scleroderma Steen VM. J Clin Rheumatol 2005;11:40-6 Time (years) SSc-ILD Which of the following DOES NOT predict lung disease progression and outcome? Anti-SCL70 positivity Low baseline FVC Fibrosis on chest High Resolution CT Mean PAP >25 mmhg (RHC) Abnormal Bronchoalveolar lavage (BAL) SSc-ILD: Facts to Remember Non-white ethnicity and anti-topoisomerase (Scl70) and anti-u3-rnp positive patients have worse lung disease (Gelber Ann Rheum Dis 2013) Baseline FVC may predict lung function decline and survival (Plastiras A&R 2006; Goh Am J Respir Crit Care Med 2008) 5
6 Probability of NOT decreasing FVC % of predicted 10/28/2013 Baseline FVC predicts pulmonary function decline and survival FVC 80% FVC 80% Time from diagnosis (years) Plastiras A&R 2006 SSc-ILD: Facts to Remember Non-white and anti-topoisomerase (Scl70) and anti-u3-rnp positive patients have worse disease (Gelber Ann Rheum Dis 2013) Baseline FVC may predict lung function decline and survival (Plastiras A&R 2006; Goh Am J Respir Crit Care Med 2008) Fibrosis on HRCT predicts worse outcome (SLS study; Goh Am J Respir Crit Care Med 2008) Goh Am J Respir Crit Care Med 2008 SSc-ILD: Facts to Remember Non-white and anti-topoisomerase (Scl70) and anti-u3-rnp positive patients have worse disease (Gelber Ann Rheum Dis 2013) Baseline FVC may predict lung function decline and survival (Plastiras A&R 2006; Goh Am J Respir Crit Care Med 2008) Fibrosis on HRCT predicts worse outcome (SLS study; Goh Am J Respir Crit Care Med 2008) BAL analysis may help define disease but does not predict long-term outcome (Mitto et al A&R 2007) BAL alveolitis does not predict long-term outcome in SLS-ILD Scleroderma Lung Study (SLS) Placebo Arm 141 pts 101 BAL positive 40 BAL negative Positive BAL alveolitis >3.0% neutrophils and/or >2.0% eosinophils) Strange C. Am J Respir Crit Care Med 2008 SSc-dyspnea SSc-Interstitial Lung Disease Which of the following DOES NOT predict lung disease progression and outcome? Anti-SCL70 positivity Low baseline FVC Fibrosis on chest High Resolution CT Mean PAP >25 mmhg (RHC) Abnormal Bronchoalveolar lavage (BAL) 80% 75% 70% 65% 55% 50% 45% 40% 68% 62% MMF 1000bid MMF 500bid DLCO FVC How would you treat this patient? 6
7 % of predicted % of predicted 10/28/2013 Scleroderma - Interstitial Lung Disease Treatment Options Immunosuppression alone (non-selective or targeted) Cyclophosphamide (daily vs. IV monthly) Mycophenolate Mofetil Scleroderma Lung Study (SLS) II Autologous Hematopoietic stem cell transplantation (safety?) Rituximab (efficacy?) Anti-fibrotic therapy Anti-cytokines: IL-13, CTGF Tyrosine Kinase inhibitors: Imatinib, Dasatinib Endothelin Receptor Antagonist: Bosentan Anti-Thrombin Pirfenidone Scleroderma Lung Study (SLS) CYC vs. placebo FVC % pp Trial stop Combination therapy? Tashkin et al Am J Resp Ctir care Med 2007 Scleroderma - Interstitial Lung Disease Treatment Options Immunosuppression alone (non-selective or targeted) Cyclophosphamide (daily vs. IV monthly) Mycophenolate Mofetil Scleroderma Lung Study (SLS) II Autologous Hematopoietic stem cell transplantation (safety?) Rituximab (efficacy?) Anti-fibrotic therapy Anti-cytokines: IL-13, CTGF Tyrosine Kinase inhibitors: Imatinib, Dasatinib Endothelin Receptor Antagonist: Bosentan Anti-Thrombin Pirfenidone Combination therapy? 80% 75% 70% 65% 55% 50% 45% 40% 68% MMF 1500bid SSc-Interstitial Lung Disease 62% MMF 1000bid MMF 500bid DLCO FVC How would you treat this patient? MMF=mycophenolate mofetil Case Study #3 45 yo WF with limited SSc Progressive dyspnea Scleroderma Lung Disease Early Detection 100% 90% 87% 100% 80% 70% 71% 58% 58% 64% 64% 62% 62% Functional Status 50% 46% DLCO 40% FVC Aggressive Therapy 30% 20% 10% 0% MMF CYC CYC AZA Jan-13 Jul-13 50% 100% FVC% 7
8 Scleroderma Renal Crisis How to ACE the diagnosis and management Case Study #4 58 years old Caucasian male March 2012 July 2012 August 2012 October 2012 New onset RP Scleroderma Renal Crisis Rapidly progressive skin fibrosis (UE/LE) Joint swelling and tendon friction rubs Diagnosis of diffuse Systemic Sclerosis Anti-RNA polymerase III positive Started on Prednisone 40 mg orally daily MTX 20 mg orally weekly Hypertensive urgency (210/120 mmhg) Headaches Dyspnea and chest pain Creatinine 3.4 mg/dl Anemia (Hemoglobin 9.8 g/l) Thrombocytopenia (55,000/mm 3 ) Case Study #4 Which features increase the risk for SRC in this patient? Gender Short disease course High creatinine Recent corticosteroid therapy Anti-RNA polymerase III positivity Thrombocytopenia Cardiac involvement : Facts to Remember Develops in 5-10% of SSc patients Can precede SSc diagnosis (20%) Risk factors Early diffuse skin disease (2-4 yrs from SSc onset, median 8 months) Use of corticosteroids (higher doses or low doses for prolonged time) Use of cyclosporine Anti-RNA polymerase III () Outcome Responsive to ACE inhibitors Reduction of mortality from 42% to 4 % after early 1970 s Overall 5-year mortality 30-50% Penn Q J Med 2007 Teixeira Ann Rheum Dis 2008 Steen Ann Rheum Dis 2007 Guillven L Rheumatology 2012 Case Study #4 Which features increase the risk for SRC in this patient? Gender Short disease course High creatinine Recent corticosteroid therapy Anti-RNA polymerase III positivity Thrombocytopenia Cardiac involvement : Clinical Presentation Abrupt onset of very high blood pressure (>150/90 mmhg) Sudden renal failure (raising serum creatinine, mild proteinuria) Features of malignant hypertension headache malaise retinopathy encephalopathy (lethargy, confusion, seizures) CHF/Pulmonary edema Anemia, thrombocytopenia 8
9 Which of the following features is NOT associated with SRC? Normal blood pressure Normal renal function Anti-U3-RNP positivity Reduced ADAMTS13 Pericardial effusion : Clinical Presentation SRC Typical Features Very high blood pressure (>150/90 mmhg) Sudden renal failure Malignant hypertension and CHF Hemolytic anemia and/or thrombocytopenia SRC Atypical Features Without renal failure (early) Without hypertension (10%) Asymptomatic pericardial effusion With or without renal failure or hypertension Which of the following clinical features is not associated with SRC? Normal blood pressure Normal renal function Anti-U3-RNP positivity ADAMTS13 positive test Pericardial effusion ADAMTS13 Markedly decreased (<10%) or absent in TTP patients, normal in SSc Renal Crisis Worse prognosis Males Creatinine >3 mg/dl at presentation Normotensive SRC Cardiac involvement Prior use ACE inhibitors Worse response to Rx Cardiac involvement Myocarditis, arrhythmias Denton C P et al. Rheumatology 2009 Presentation 25% Dialysis 75% Medical Therapy Early phase (< 24m) 75% 25% Medical Therapy Dialysis Management 30% of SRC patients do not respond adequately to ACE inhibitors Long term outcome (>24m) 40% Dialysis Medical Therapy Steen VD et al. Ann Intern Med 1990 Penn H et al. QJM 2007 Teixeira L et al. Ann Rheum Dis 2008 Batal I et al. Int J Rheumatol
10 Difficult to control or refractory SRC (30%) Management ACE inhibitors Calcium Channel Blockers Angiotensin Receptor Blockers (ARBs) ET receptor blockers initial therapy Combination, escalate dose Not effective alone Step-up therapy with ACEi Combination Small pilot, safety/rationale Prostacyclin IV infusion Anecdotal Plasma Exchange New drugs? If TTP present Untested for SRC Caskey Lancet 1997 Cheung Am J Kidney Dis 2005 Penn QJM 2013 Mouthon Hum Pathol 2011 Riociguat Guanylate cyclase stimulator Ghofraini N Engl J Med 2013 Direct renin inhibitors (i.e. aliskiren) Contraindication combo with ACE/ARBs in renal failure Staessen Lancet Start short-acting ACEi goal sys BP 20mmHg/24hr (avoid hypotension) Maximize ACEi dose Additional therapy: ARBs CCB ETA IV prostacyclin no response no response Accelerated hypertension >150/85 mmhg response no response Hospitalization Monitor renal function Renal Failure Hemodialysis Kidney transplant Progressive renal impairment Renal biopsy confirm diagnosis measure damage prognosis Assess for kidney function improvement up to 24 months after SRC Recovery Thanks 10
SCLERODERMA. Scleroderma update. No disclosures or conflicts. Leslie Kahl, M.D. April 10, 2015
Scleroderma update Leslie Kahl, M.D. April 10, 2015 No disclosures or conflicts KT is a 45 year old woman who developed puffiness in her fingers 1/2013 and carpal tunnel syndrome and arthralgias 3/2013.
More informationDisclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease
Disclosures Clinical Approach: Evaluating CTD-ILD for the pulmonologist Industry relationships: Actelion, atyr Pharma, Boehringer-Ingelheim, Genentech- Roche, Gilead Aryeh Fischer, MD Associate Professor
More informationPeripheral (digital) vasculopathy in systemic. sclerosis. Ariane Herrick
Peripheral (digital) vasculopathy in systemic sclerosis Ariane Herrick Raynaud s phenomenon VASOPASM DEOXYGENATION REPERFUSION Main causes of RP Primary (idiopathic) Connective tissue diseases, including
More informationSCLERODERMA RENAL CRISIS. Presented by : Nouf Alanazi
SCLERODERMA RENAL CRISIS Presented by : Nouf Alanazi Agenda Prevalence Risk factors Pathology Diagnosis Prevention & monitoring Treatment Outcome & mortality. Summary & recommendations References SRC Abrupt
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies A Rheumatologist s Approach to Interstitial Lung Disease Outline ILD classification and patterns in CTD The clinical landscape and
More informationSCLERODERMA: An Update. What You Need To Know
SCLERODERMA: An Update What You Need To Know Pre Test Question #1 The onset of systemic sclerosis is typically: A. In the 1st decade of life B. Between the 4th and 6th decade C. Equal in all age groups
More informationScleroderma and PAH Overview. PH Resource Network Martha Kingman, FNP C UTSW Medical Center at Dallas
Scleroderma and PAH Overview PH Resource Network 2007 Martha Kingman, FNP C UTSW Medical Center at Dallas Scleroderma and PAH Outline: Lung involvement in scleroderma Evaluation of the scleroderma patient
More informationMyositis and Your Lungs
Myositis and Your Lungs 2013 TMA Annual Patient Meeting Louisville, Kentucky Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Myositis Heterogeneous group of autoimmune syndromes
More informationUpdate in Systemic Sclerosis! Lauren Kim MD! NW Rheumatology Associates
Update in Systemic Sclerosis! Lauren Kim MD! NW Rheumatology Associates Review Systemic sclerosis affects approximately 75,000 to 100,000 people in the U.S. and has the highest mortality rate of any autoimmune
More informationCase Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco
Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary
More informationScleroderma. Nomenclature Synonyms. Scleroderma. Progressive Systemic Sclerosis. Systemic Sclerosis. Edward Dwyer, M.D. Division of Rheumatology
Scleroderma Edward Dwyer, M.D. Division of Rheumatology Nomenclature Synonyms Scleroderma Progressive Systemic Sclerosis Systemic Sclerosis Scleroderma 1 Scleroderma Chronic systemic autoimmune disease
More informationScleroderma. Nomenclature Synonyms. Scleroderma. Progressive Systemic Sclerosis. Systemic Sclerosis. Limited vs. Diffuse Scleroderma.
Scleroderma Edward Dwyer, M.D. Division of Rheumatology Nomenclature Synonyms Scleroderma Progressive Systemic Sclerosis Systemic Sclerosis Scleroderma Chronic systemic autoimmune disease characterized
More informationNOT COPY. Choice of the primary outcome: Pro Lung 03/09/2018. Lung assessment in clinical trials
Choice of the primary outcome: Pro Lung Christopher P. Denton Professor of Experimental Rheumatology Royal Free Hospital and University College London, UK Florence 7 th September 218 Improved clinical
More informationThomas A. Medsger, Jr., MD University of Pittsburgh School of Medicine. Disclosures: None
Thomas A. Medsger, Jr., MD University of Pittsburgh School of Medicine Disclosures: None 1. idiopathic interstitial pneumonitis (IIP) - 30% of all ILD - most common form is idiopathic pulmonary fibrosis
More informationCTD-related Lung Disease
13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of
More informationPredictors of Isolated Pulmonary Hypertension in Patients With Systemic Sclerosis and Limited Cutaneous Involvement
ARTHRITIS & RHEUMATISM Vol. 48, No. 2, February 2003, pp 516 522 DOI 10.1002/art.10775 2003, American College of Rheumatology Predictors of Isolated Pulmonary Hypertension in Patients With Systemic Sclerosis
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationSCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW
SCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW Lung disease can be a serious complication of scleroderma. The two most common types of lung disease in patients with scleroderma are interstitial
More information9/15/11. Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September Scleroderma. Hard skin
Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September 2011 Scleroderma Hard skin 1 No diagnostic test for scleroderma Pathogenesis is unknown prominent features of disease reflect
More informationSCLERODERMA SPECTRUM DISEASE
SCLERODERMA SPECTRUM DISEASE Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor King Saud University President of the Charitable Association for Rheumatic Diseases Agenda Background
More informationManagement of scleroderma renal crisis. Voon Ong Senior Clinical Lecturer Royal Free Hospital and UCL Medical School, London, UK
Management of scleroderma renal crisis Voon Ong Senior Clinical Lecturer Royal Free Hospital and UCL Medical School, London, UK Overview Presentation of SRC Diagnosis and management Pathogenesis Predictors
More informationPulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationdifferent phenotypes
Pulmonary hypertension in scleroderma: different phenotypes UMR 995 Pr David LAUNAY, MD, PhD launayd@gmail.com Service de Médecine Interne. Unité d'immunologie Clinique CNRMR Maladies Systémiques et Autoimmunes
More informationSystemic sclerosis and GI involvement
Systemic sclerosis and GI involvement Dr Maggie Larché, MRCP(UK), PhD Associate Professor, Division of Rheumatology, McMaster University St Joseph s Hospital Scleroderma CME, St Joseph s Hospital, September
More information10 pearls in scleroderma for the family practitioner
10 pearls in scleroderma for the family practitioner Dr Maggie Larche, MRCP(UK), PhD Associate Professor, Division of Rheumatology, McMaster University St Joseph s Hospital Family Medicine Rounds, St Joseph
More informationSCLERODERMA 101. Maureen D. Mayes, MD, MPH Professor of Medicine University of Texas - Houston
SCLERODERMA 101 Maureen D. Mayes, MD, MPH Professor of Medicine University of Texas - Houston TYPES OF SCLERODERMA Localized versus Systemic Two Kinds of Scleroderma Localized Scleroderma Morphea Linear
More informationOverview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy
Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe
More informationMethodology used to develop new ACR-EULAR criteria. Disclosures. Objectives Guiding principles underlying methodology
Methodology used to develop new ACR-EULAR criteria Sindhu Johnson MD PhD Toronto Scleroderma Program University of Toronto Co-convenors Janet Pope Frank van den Hoogen Members Jaap Fransen Sindhu Johnson
More informationScholars Journal of Medical Case Reports
Scholars Journal of Medical Case Reports Sch J Med Case Rep 2015; 3(9B):928-932 Scholars Academic and Scientific Publishers (SAS Publishers) (An International Publisher for Academic and Scientific Resources)
More informationSystemic sclerosis (SSC)
Systemic sclerosis (SSC) -Is a multi system autoimmune disease, characterized by fibrosis of the skin and variable pattern of other visceral -SSC: Is a relatively UN common disease -Prevalence in U S A
More information4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
More informationINTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
More informationA Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco
A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Why it is important Definition/Classification
More informationDisclosures. Integrated Approach to Treating CTD-ILD. Limitations. Relevant items to consider. Other than for SSc-ILD, no controlled data
Integrated Approach to Treating CTD-ILD Industry relationships: Disclosures Aryeh Fischer, MD Associate Professor of Medicine Division of Rheumatology Division of Pulmonary Sciences and Critical Care Medicine
More informationChayawee Muangchan MD. Division of Rheumatology, Department of Medicine Siriraj Hospital, Faculty of Medicine, Mahidol University
Chayawee Muangchan MD. Division of Rheumatology, Department of Medicine Siriraj Hospital, Faculty of Medicine, Mahidol University Systemic sclerosis: epidemiology (1) 6 5 UCTD MCTD 1 RA CTD 4 DM PM 2 3
More informationBSR and BHPR guideline for the treatment of systemic sclerosis
BSR and BHPR guideline for the treatment of systemic sclerosis Christopher P. Denton, Michael Hughes, Nataliya Gak, Josephine Vila, Maya Buch, Kuntal Chakravarty, Kim Fligelstone, Luke L Gompels, Bridget
More informationLung Involvement In Systemic Sclerosis. Milind Y Nadkar, Nayan K Desai INTRODUCTION
Lung Involvement In Systemic Sclerosis Milind Y Nadkar, Nayan K Desai INTRODUCTION Systemic sclerosis (SSc) is a multisystem connective tissue disease of unknown etiology. Similar to other connective tissue
More informationA Review of Interstitial Lung Diseases
Outline A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Overview of diagnosis in ILD Why it is important Definition/Classification
More informationHypertensives Emergency and Urgency
Hypertensives Emergency and Urgency Budi Yuli Setianto Cardiology Divisision Department of Internal Medicine Faculty of Medicine UGM Sardjito Hospital Yogyakarta Background USA: Hypertension is 30% of
More informationSclérodermie systémique: Manifestations musculosquelettiques
Sclérodermie systémique: Manifestations musculosquelettiques Benjamin Chaigne Service de Médecine Interne, hôpital Cochin, Centre de Référence Vascularites nécrosantes et sclérodermie systémique Assistance
More informationRHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center
RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases
More informationTHERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines
THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines Vu Nang Phuc, MD Dinh Duc Huy, MD Pham Nguyen Vinh, MD, PhD, FACC Tam Duc Cardiology Hospital Faculty Disclosure No conflict of interest
More informationManagement of Co morbidities in Idiopathic Pulmonary Fibrosis. Disclosures
Management of Co morbidities in Idiopathic Pulmonary Fibrosis Joyce S. Lee, MD MAS Director, Interstitial Lung Disease Clinic University of California, San Francisco Disclosures Intermune, advisory board
More informationThe Power of the ANA. April 2018 Emily Littlejohn, DO MPH
Emergent Rheumatologic Diseases and Disorders for Primary Care. The Power of the ANA April 2018 Emily Littlejohn, DO MPH Question 1: the ANA test is: A) A screening test with high specificity to diagnose
More informationReporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation
Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation Marcelo C. Pasquini, MD, MSc HVD05_1.ppt Outline Review of autoimmune diseases (AID). Role of transplantation for AID Data collection:
More informationMultidisciplinary Diagnosis in Action: Challenging Case Presentations
Multidisciplinary Diagnosis in Action: Challenging Case Presentations Interstitial Lung Disease: Advances in Diagnosis and Management UCSF CME November 8, 2014 Case 1 69 yo M 3 year history of intermittent
More informationNintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis
Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis Brad Zimmermann, PharmD, MBA Pharmacy Grand Rounds May 02, 2017 Rochester, Minnesota 2017 MFMER slide-1 Objectives
More informationCASE REPORT. Norihiro Nagamura 1 and Seikon Kin 2. Department of Rheumatology and Allergy, Shimane Prefectural Central Hospital, Izumo, Japan 2
Nagoya J. Med. Sci. 78. 329 ~ 334, 2016 CASE REPORT Scleroderma renal crisis during intravenous cyclophosphamide pulse therapy for complicated interstitial lung disease was successfully treated with angiotensin
More informationSCLERODERMA EPIDEMIOLOGY
1 SCLERODERMA Scleroderma is an autoimmune disorder of unknown etiology, characterized by fibrosis and microvascular injury in affected organs. The hallmark of the disease is thickening and tightness of
More informationSEVERE ORGAN INVOLVEMENT IN SYSTEMIC SCLEROSIS WITH DIFFUSE SCLERODERMA
ARTHRITIS & RHEUMATISM Vol. 43, No. 11, November 2000, pp 2437 2444 2000, American College of Rheumatology 2437 SEVERE ORGAN INVOLVEMENT IN SYSTEMIC SCLEROSIS WITH DIFFUSE SCLERODERMA VIRGINIA D. STEEN
More informationSecondary Raynaud s Phenomenon
Secondary Raynaud s Phenomenon Ulf Müller-Ladner University of Giessen Kerckhoff Clinic Bad Nauheim Germany Clinical problems in SSc Therapeutic solutions? Pulmonary fibrosis + PAH Diffuse Pulmonary fibrosis,
More informationFinancial Interest Disclosure (over the past 24 months) Before we begin. Background What is ILD? 8/18/2016
Financial Interest Disclosure (over the past 24 months) SCLERODERMA LUNG DISEASE UPDATE Company Speaker Advisory Research Boehringer-Ingelheim September 2016 Hoffman La-Roche Intermune Shane Shapera, MD,
More informationRecent Treatment of Pulmonary Artery Hypertension. Cardiology Division Yonsei University College of Medicine
Recent Treatment of Pulmonary Artery Hypertension Cardiology Division Yonsei University College of Medicine Definition Raised Pulmonary arterial pressure (PAP) WHO criteria : spap>40 mmhg NIH Criteria
More informationUpdate on Therapies for Idiopathic Pulmonary Fibrosis. Outline
Update on Therapies for Idiopathic Pulmonary Fibrosis Paul Wolters Associate Professor University of California, San Francisco Outline Classification of Interstitial lung disease Clinical classification
More informationScleroderma FAQ. About this Document
Scleroderma FAQ About this Document The Scleroderma FAQ * is a comprehensive document that covers systemic scleroderma diagnosis and treatment. All information contained in the FAQ is based on current
More informationSystemic lupus erythematosus (SLE): Pleuropulmonary Manifestations
08/30/10 09/26/10 Systemic lupus erythematosus (SLE): Pleuropulmonary Manifestations Camila Downey S. Universidad de Chile, School of Medicine, Year VII Harvard University, School of Medicine Sept 17,
More informationLines and crackles. Making sense of ILD
Lines and crackles Making sense of ILD Case JM 65 year old male Gradual shortness of breath, going on over a year Some dry cough Ex-smoker, quit 10 years ago Crackles in the bases CXR presented Sent to
More informationDeterminants of pulmonary function improvement in patients with scleroderma and interstitial lung disease
Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease G.E. Tzelepis, S.C. Plastiras, S.P. Karadimitrakis, P.G. Vlachoyiannopoulos Department of Pathophysiology,
More informationLupus Related Kidney Diseases. Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017
Lupus Related Kidney Diseases Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017 Financial Disclosures MedImmune Lupus Nephritis Kidney Biopsy Biomarkers
More informationA Comparison Between Anti-Th/To and Anticentromere Antibody Positive Systemic Sclerosis Patients With Limited Cutaneous Involvement
ARTHRITIS & RHEUMATISM Vol. 48, No. 1, January 2003, pp 203 209 DOI 10.1002/art.10760 2003, American College of Rheumatology A Comparison Between and Anticentromere Antibody Positive Systemic Sclerosis
More informationDocSpot what patients want to know
DocSpot what patients want to know Professor Chris Denton Royal Free Hospital London, UK Madrid, February 2012 Copyright 2011 Raynaud's & Scleroderma Association. Charity Reg. No. 326306 DocSpot Live!
More informationA case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel
A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical
More informationEmerging Therapies for Lung Fibrosis. Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow
Emerging Therapies for Lung Fibrosis Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow Lung Fibrosis/Interstitial Lung Disease Disease that affects the tissue that supports the lungs alveoli
More informationConnective tissue disease related Pulmonary arterial hypertension
Connective tissue disease related Pulmonary arterial hypertension DM Seminar: Dr.Vamsi Krishna PAH in connective tissue diseases CTD accounts for 30% of PAH according to US PAH registry. Incidence is on
More informationScleroderma renal crisis following silicone breast implant rupture: a case report and review of the literature
CASE REPORT Clinical and Experimental Rheumatology 2014; 32: 262-266. Scleroderma renal crisis following silicone breast implant rupture: a case report and review of the literature G. Al Aranji¹, D. White¹,
More informationPulmonary veno-occlusive disease
Disclosure Objectives Pulmonary veno-occlusive disease Tilman Humpl The Hospital for Sick Children University of Toronto, Canada Advisor/Research Grants Actelion Pfizer Historical aspects Epidemiology/Genetics
More informationassociated conditions a closer look at connective tissue disease and PAH
associated conditions a closer look at connective tissue disease and PAH The link between connective tissue disease and PAH Those living with a connective tissue disease (CTD) have an increased risk of
More informationSarcoidosis Case. Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA. WASOG: educational material
Sarcoidosis Case Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA WASOG: educational material Sarcoidosis Case patient is a Caucasian male age 46 was diagnosed
More informationHypersensitivity Pneumonitis (HP)
Hypersensitivity Pneumonitis (HP) Information for patients and families UHN Read this handout to learn about: What hypersensitivity pneumonitis (HP) is Signs and symptoms How your doctor will know if you
More informationPulmonary arterial hypertension. Pulmonary arterial hypertension: newer therapies. Definition of PH 12/18/16. WHO Group classification of PH
Pulmonary arterial hypertension Pulmonary arterial hypertension: newer therapies Ramona L. Doyle, MD Clinical Professor of Medicine, UCSF Attending Physician UCSF PH Clinic Definition and classification
More informationEvidence Review: Title. Month/ Year. Evidence Review:
Evidence Review: Title Month/ Year Evidence Review: Rituximab for connective tissue disease associated interstitial lung disease October 2014 Standard Operating Procedure: NHS England Evidence Review:
More informationS ystemic sclerosis (SSc), also called
CASE IN POINT The Clinical Pathophysiology of Chronic Aaron Reyes; and Leila Hashemi, MD Primary care providers should monitor disease progression in the skin and in the pulmonary, renal, cardiac, and
More informationSystemic sclerosis (SSc) is a systemic autoimmune
Eur Respir Rev 2013; 22: 127, 6 19 DOI: 10.1183/09059180.00005512 CopyrightßERS 2013 EUROPEAN RESPIRATORY UPDATE Scleroderma lung disease Joshua J. Solomon*, Amy L. Olson*, Aryeh Fischer*, Todd Bull #,
More informationInterstitial Lung Disease
Interstitial Lung Disease Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 130 disorders which are characterized by scarring (i.e. fibrosis ) and/or inflammation
More informationAutoantibodies in the Idiopathic Inflammatory Myopathies
Autoantibodies in the Idiopathic Inflammatory Myopathies Steven R. Ytterberg, M.D. Division of Rheumatology Mayo Clinic Rochester, MN The Myositis Association Annual Conference St. Louis, MO Sept. 25,
More informationSystemic Hypertension Dr ahmed almutairi Assistant professor Internal medicine dept
Systemic Hypertension Dr ahmed almutairi Assistant professor Internal medicine dept Continents 1- introduction 2- classification/definition 3- classification/etiology 4-etiology in both categories 5- complications
More informationHigh Impact Rheumatology
High Impact Rheumatology Systemic Lupus Erythematosus Bernard Rubin, DO MPH Case 1: History A 45-year-old woman presents with severe dyspnea and cough. She was in excellent health until 4 weeks ago when
More informationCase Studies. Scleroderma Renal Crisis or Thrombotic Thrombocytopenic Purpura: Seeing Through the Masquerade. Patient 1
Scleroderma Renal Crisis or Thrombotic Thrombocytopenic Purpura: Seeing Through the Masquerade Emily Keeler, DO, 1* Gloria Fioravanti, DO, FACP, 1 Bensson Samuel, MD, PG Dip, 1 Santo Longo, MD 2 Lab Med
More informationAutoimmune diseases. SLIDE 3: Introduction to autoimmune diseases Chronic
SLIDE 3: Introduction to autoimmune diseases Chronic Autoimmune diseases Sometimes relapsing : and remitting. which means that they present as attacks Progressive damage Epitope spreading more and more
More informationGuide for New and Future Patients
Guide for New and Future Patients About this Guide This Guide for New and Future Patients is a companion document to the Scleroderma FAQ TM, also available through the Scleroderma Education Project website:
More informationNon-commercial use only
ORIGINAL Reumatismo, 2013; 65 (4): 186-191 Prospective capillaroscopy-based study on transition from primary to secondary Raynaud s phenomenon: preliminary results E. Bernero, A. Sulli, G. Ferrari, F.
More information[ Original Research Diffuse Lung Disease ]
[ Original Research Diffuse Lung Disease ] Predicting Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease Using Risk Prediction Models Derived From Idiopathic Pulmonary Fibrosis Christopher
More informationHypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas
Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas Rishi Raj MD Director, Interstitial Lung Diseases Program Clinical Professor of Pulmonary and Critical Care Medicine Stanford University
More informationUK Scleroderma Study Group (UKSSG) Guidelines on the Diagnosis and Management of Scleroderma Renal Crisis
Title UK Scleroderma Study Group (UKSSG) Guidelines on the Diagnosis and Management of Scleroderma Renal Crisis Authors Bernadette M. Lynch, MD, MRCPI 1 Edward P. Stern 1 Voon Ong 1 Mark Harber 2 Aine
More informationProtocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year
PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart
More informationINTERSTITIAL LUNG DISEASE Dr. Zulqarnain Ashraf
Indep Rev Jul-Dec 2018;20(7-12) Dr. Zulqarnain Ashraf IR-653 Abstract: ILD is a group of diseases affect interstitium of the lung. Repeated insult to the lung cause the interstitium to be damaged. Similarly
More informationDisclosures. Rheumatological Approaches to Differential Diagnosis, Physical Examination, and Interpretation of Studies. None
Rheumatological Approaches to Differential Diagnosis, Physical Examination, and Interpretation of Studies Sarah Goglin MD Assistant Professor of Medicine Division of Rheumatology Disclosures None 1 [footer
More informationOPTION 1 SF-DCT INFORMATION FOR MIXED CONNECTIVE TISSUE DISEASE (MCTD) CLAIMS. (MCTD claims are not eligible for Disease Option 2)
SF-DCT INFORMATION FOR MIXED CONNECTIVE TISSUE DISEASE (MCTD) CLAIMS OPTION 1 (MCTD claims are not eligible for Disease Option 2) 1 Mixed Connective Tissue Disease (MCTD) Mixed Connective Tissue Disease
More informationThe scleroderma lung: where do we stand?
6th international meeting on pulmonary rare diseases and orphan drugs Milan 27-28 February 2015 The scleroderma lung: where do we stand? Silvia Bellando Randone & Marco Matucci Cerinic Dept of Experimental
More informationUnderstanding Myositis Medications
Understanding Myositis Medications 2015 TMA Annual Patient Conference Orlando, Florida Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Disclosures Mallinckrodt: Research Grant Genentech:
More informationA Patient s Guide to Understanding Pulmonary Arterial Hypertension in Systemic Sclerosis
A Patient s Guide to Understanding Pulmonary Arterial Hypertension in Systemic Sclerosis Compared with the general population, patients with systemic sclerosis (also known as scleroderma) have a higher
More informationBMI ( ) kg / m 2 (P < 0.001) OSAS ( ) ( ) cm P < OSAS OSAS
CHEST Luca Busetto, MD; Giuliano Enzi, MD; Emine Meral Inelmen, MD; Gabriella Costa, MD; Valentina Negrin, MD; Giuseppe Sergi, MD; and Andrea Vianello, MD (OSAS) OSAS 17 OSAS (BMI) (55.8 9.9) kg / m 2
More informationEssential Rheumatology. Dr Ellen Bruce Consultant Rheumatologist CMFT
Essential Rheumatology Dr Ellen Bruce Consultant Rheumatologist CMFT Saving the best for last! Apparently people recall best the first and last thing they re told. Far too difficult to include everything.
More informationUIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION!
UIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION! STÉPHANE JOUNEAU 11 JULY 2014 Respiratory Medicine Department, Pontchaillou Hospital, Rennes, France CASE OVERVIEW This case highlights how a usual
More informationTBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than
TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients
More informationRheumatology Primer: What Labs and When
Rheumatology Primer: What Labs and When Irina Konon, MD Department of Internal Medicine Division of Rheumatology Medical College of Wisconsin Disclosures None 1 Objective Discuss principles of laboratory
More informationSupplementary Online Content
Supplementary Online Content Caglayan E, Axmann S, Hellmich M, Moinzadeh P, Rosenkranz S. Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebocontrolled crossover study.
More informationNora Goldschlager, M.D. SFGH Division of Cardiology UCSF
CLASSIFICATION OF HEART FAILURE Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF DISCLOSURES: NONE CLASSIFICATION C OF HEART FAILURE NYHA I IV New paradigm Stage A: Pts at high risk of developing
More informationHaving a stem cell transplant for scleroderma a patient and doctor perspective
Having a stem cell transplant for scleroderma a patient and doctor perspective Professor Chris Denton, On behalf of an excellent team across UCLPartners Royal Free Hospital and University College London,
More informationTHE KIDNEY AND SLE LUPUS NEPHRITIS
THE KIDNEY AND SLE LUPUS NEPHRITIS JACK WATERMAN DO FACOI 2013 NEPHROLOGY SIR RICHARD BRIGHT TERMINOLOGY RENAL INSUFFICIENCY CKD (CHRONIC KIDNEY DISEASE) ESRD (ENDSTAGE RENAL DISEASE) GLOMERULONEPHRITIS
More information